Scher N, Boudabous H, Partouche J, Rezaee-Vessal S, Ihout P, Rizzo C
Support Care Cancer. 2024; 32(11):743.
PMID: 39436413
DOI: 10.1007/s00520-024-08929-x.
Chang H, Liou Y, Sun D
Tzu Chi Med J. 2024; 36(4):349-359.
PMID: 39421490
PMC: 11483098.
DOI: 10.4103/tcmj.tcmj_100_24.
Hirose T, Ito M, Tsuchihashi K, Ozaki Y, Nishio H, Ichihara E
Int J Clin Oncol. 2024; 29(8):1081-1087.
PMID: 38904887
DOI: 10.1007/s10147-024-02572-6.
Hirose T, Ito M, Tsuchihashi K, Ozaki Y, Nishio H, Ichihara E
Int J Clin Oncol. 2024; 29(8):1067-1073.
PMID: 38865026
DOI: 10.1007/s10147-024-02569-1.
Yoshinami T, Nozawa K, Yokoe T, Ozaki Y, Nishio H, Tsuchihashi K
Int J Clin Oncol. 2024; 29(6):681-688.
PMID: 38649648
DOI: 10.1007/s10147-024-02504-4.
The Use of Granulocyte Colony-Stimulating Factor as Primary Prophylaxis in Patients Undergoing Chemotherapy: An Experience of Moroccan Oncologists.
Kaakoua M, Boujmadi S, Belbaraka R, Essadi I
Cureus. 2024; 16(2):e54482.
PMID: 38510886
PMC: 10954314.
DOI: 10.7759/cureus.54482.
Febrile neutropenia incidence and the variable toxicity profile between brand and generic docetaxel in the adjuvant treatment of breast cancer with docetaxel and cyclophosphamide regimen.
Tarcha F, Baccarin A, Barros L, Alencar E, Del Giglio A, Silva Melo Cruz F
Einstein (Sao Paulo). 2023; 21:eAO0486.
PMID: 38126660
PMC: 10730260.
DOI: 10.31744/einstein_journal/2023AO0486.
Impact of primary prophylaxis by pegfilgrastim in diffuse large B-cell lymphoma treated with R-CHOP.
Kim M, Ahn Y, Ahn H, Ha S, Oh H, Song J
Ann Hematol. 2023; 102(11):3167-3175.
PMID: 37599323
DOI: 10.1007/s00277-023-05411-2.
Assessing the Optimal Regimen: A Systematic Review and Network Meta-Analysis of the Efficacy and Safety of Long-Acting Granulocyte Colony-Stimulating Factors in Patients with Breast Cancer.
You Z, Zhang H, Huang Y, Zhao L, Tu H, Zhang Y
Cancers (Basel). 2023; 15(14).
PMID: 37509336
PMC: 10378237.
DOI: 10.3390/cancers15143675.
Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review.
Gebremariam G, Fentie A, Beyene K, Sander B, Gebretekle G
BMC Health Serv Res. 2022; 22(1):1600.
PMID: 36585648
PMC: 9805270.
DOI: 10.1186/s12913-022-08933-z.
How I treat older patients with DLBCL in the frontline setting.
Lugtenburg P, Mutsaers P
Blood. 2022; 141(21):2566-2575.
PMID: 36413153
PMC: 10646795.
DOI: 10.1182/blood.2020008239.
Choosing Wisely Philippines: ten low-value or harmful practices that should be avoided in cancer care.
Ting F, Uy C, Bebero K, Sacdalan D, Abarquez H, Nilo G
Ecancermedicalscience. 2022; 16:1424.
PMID: 36158983
PMC: 9458260.
DOI: 10.3332/ecancer.2022.1424.
A multinational, drug utilization study of lipegfilgrastim use in real-world setting in Europe.
Kaplan S, Bogojevic D, Rainville C, Gross N
Support Care Cancer. 2022; 30(11):9191-9201.
PMID: 36044089
DOI: 10.1007/s00520-022-07341-7.
Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study.
Kowalyszyn R, Fein L, Richardet M, Varela M, Ortiz E, Micheri C
JCO Glob Oncol. 2022; 8:e2100276.
PMID: 35324270
PMC: 9071253.
DOI: 10.1200/GO.21.00276.
The Real-World Experience of the Biosimilar (Grastofil) to the Reference Biologic (Neupogen) in Breast Cancer and Lymphoma: A Canadian Single-Centre Retrospective Study.
Wong G, Wang K, Pasetka M, Zhang L, Lou J, Majeed H
Curr Oncol. 2022; 29(3):1349-1369.
PMID: 35323315
PMC: 8947031.
DOI: 10.3390/curroncol29030115.
Analysis of the Safety of Pegfilgrastim Addition in Bleomycin, Etoposide, and Cisplatin Treatment Patients With Germ Cell Tumors.
Nakagawa R, Iwamoto H, Makino T, Kadomoto S, Yaegashi H, Iijima M
Front Oncol. 2022; 11:770067.
PMID: 35070973
PMC: 8776647.
DOI: 10.3389/fonc.2021.770067.
Improving Outcomes of Chemotherapy: Established and Novel Options for Myeloprotection in the COVID-19 Era.
Lyman G, Kuderer N, Aapro M
Front Oncol. 2021; 11:697908.
PMID: 34307165
PMC: 8299941.
DOI: 10.3389/fonc.2021.697908.
Antibiotic Prophylaxis or Granulocyte-Colony Stimulating Factor Support in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.
Klein E, Sauer S, Klein S, Tichy D, Benner A, Bertsch U
Cancers (Basel). 2021; 13(14).
PMID: 34298654
PMC: 8303829.
DOI: 10.3390/cancers13143439.
Risk factors for neutropenic fever in non-Hodgkin's lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis.
Kim Y, Kim S, Park Y, Oh S, Yun H, Mun Y
Korean J Intern Med. 2021; 36(5):1181-1189.
PMID: 34265889
PMC: 8435507.
DOI: 10.3904/kjim.2020.206.
Pooled Analysis on the Effectiveness and Safety of Lipegfilgrastim in Patients With Urological Malignancies in the Real-World Setting.
Merseburger A, Geiges G, Klier J, Wiesholzer M, Pichler P
Front Oncol. 2021; 11:655355.
PMID: 34123810
PMC: 8195268.
DOI: 10.3389/fonc.2021.655355.
